Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A novel glycoprotein obtained from Chlorella vulgaris strain CK22 shows antimetastatic immunopotentiation.

Tanaka K, Yamada A, Noda K, Hasegawa T, Okuda M, Shoyama Y, Nomoto K.

Cancer Immunol Immunother. 1998 Feb;45(6):313-20.

PMID:
9490201
2.

Protective effect of an acidic glycoprotein obtained from culture of Chlorella vulgaris against myelosuppression by 5-fluorouracil.

Konishi F, Mitsuyama M, Okuda M, Tanaka K, Hasegawa T, Nomoto K.

Cancer Immunol Immunother. 1996 Jun;42(5):268-74.

PMID:
8706047
3.

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ.

J Immunol. 2003 Nov 15;171(10):5051-63.

4.

Simple assay for antitumour immunoactive glycoprotein derived from Chlorella vulgaris strain CK22 using ELISA.

Noda K, Tanaka K, Yamada A, Ogata J, Tanaka H, Shoyama Y.

Phytother Res. 2002 Sep;16(6):581-5.

PMID:
12237820
5.

Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.

Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S.

Int Immunol. 2000 Aug;12(8):1145-55.

PMID:
10917889
6.

Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites.

Tanigawa K, Takeshita N, Craig RA, Phillips K, Knibbs RN, Chang AE, Stoolman LM.

J Immunol. 2001 Sep 15;167(6):3089-98.

7.
8.

In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.

Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori C, Ichihashi M.

Exp Dermatol. 2004 Oct;13(10):613-20.

PMID:
15447721
9.

Toll-like receptor 2 is at least partly involved in the antitumor activity of glycoprotein from Chlorella vulgaris.

Hasegawa T, Matsuguchi T, Noda K, Tanaka K, Kumamoto S, Shoyama Y, Yoshikai Y.

Int Immunopharmacol. 2002 Mar;2(4):579-89.

PMID:
11962736
10.

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borrás-Cuesta F, Lasarte JJ.

J Immunol. 2003 Dec 1;171(11):5931-9.

11.

Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.

Tanaka H, Tanaka J, Kjaergaard J, Shu S.

J Immunother. 2002 May-Jun;25(3):207-17.

PMID:
12000862
12.
13.

Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.

Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA.

J Immunol. 2000 Nov 15;165(10):5738-49.

14.
15.
18.

Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

Gollob JA, Schnipper CP, Orsini E, Murphy E, Daley JF, Lazo SB, Frank DA, Neuberg D, Ritz J.

J Clin Invest. 1998 Aug 1;102(3):561-75.

19.

Oral administration of Chlorella vulgaris augments concomitant antitumor immunity.

Tanaka K, Tomita Y, Tsuruta M, Konishi F, Okuda M, Himeno K, Nomoto K.

Immunopharmacol Immunotoxicol. 1990;12(2):277-91.

PMID:
2229925
20.

FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.

Hofmann M, Brinkmann V, Zerwes HG.

Int Immunopharmacol. 2006 Dec 20;6(13-14):1902-10. Epub 2006 Aug 30.

PMID:
17161343

Supplemental Content

Support Center